Shinjo Keiko, Kondo Yutaka
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan.
Methods Mol Biol. 2012;863:221-39. doi: 10.1007/978-1-61779-612-8_13.
Besides known genetic aberrations, epigenetic alterations have emerged as common hallmarks of many cancer types, including lung cancer. Epigenetics is a process involved in gene regulation, mediated via DNA methylation, histone modification, chromatin remodeling, and functional noncoding RNAs, which influences the accessibility of the underlying DNA to transcriptional regulatory factors that activate or repress expression. Studies have shown that epigenetic dysregulation is associated with multiple steps during carcinogenesis. Since epigenetic therapy is now in clinical use in hematopoietic diseases and undergoing trials for lung cancer, a better understanding of epigenetic abnormalities is desired. Recent technologies for high-throughput genome-wide analyses for epigenetic modifications are promising and potent tools for understanding the global dysregulation of cancer epigenetics. In this chapter, studies of epigenetic abnormality and its clinical implication in lung cancers are discussed.
除了已知的基因畸变外,表观遗传改变已成为包括肺癌在内的多种癌症类型的共同特征。表观遗传学是一个涉及基因调控的过程,通过DNA甲基化、组蛋白修饰、染色质重塑和功能性非编码RNA介导,影响潜在DNA对激活或抑制表达的转录调节因子的可及性。研究表明,表观遗传失调与致癌过程中的多个步骤相关。由于表观遗传疗法目前已在血液系统疾病中临床应用,并正在进行肺癌试验,因此需要更好地了解表观遗传异常。用于表观遗传修饰的高通量全基因组分析的最新技术是理解癌症表观遗传学全局失调的有前景且强大的工具。在本章中,将讨论肺癌表观遗传异常及其临床意义的研究。